Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT study
Summary What is this summary about? Sparsentan (FILSPARI ® ) is a once-daily pill for people with Immunoglobulin A (IgA) nephropathy who are at high risk for worsening kidney disease. Early results from a research study (clinical trial) called PROTECT showed that after 9 months of treatment, sparsen...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2025-07-01
|
| Seri Bilgileri: | Therapeutic Advances in Rare Disease |
| Online Erişim: | https://doi.org/10.1177/26330040251355613 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|